Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses.
All vial doses, including the new 12.5 mg and 15 mg options, will be priced at $499 per month or less through the Zepbound self-pay program, according to a June 16 news release from the drugmaker. The 2.5 mg starter dose will remain priced at $349 for the first month of treatment.
In clinical trials, patients on the 15 mg dose lost an average of 48 pounds, the release said. The new vial joins existing single-dose pens currently on the market.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
